Healthcare / Diagnostics & Research
Exclusive insider sentiment analysis for the Diagnostics & Research sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:00 | 2026-04-01 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | Diagnostics & Research | SALE | $51.00 | 1,000 | $51,000 | 25,722 | -3.7% |
| 2026-04-04 01:05 | 2026-04-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Officer; PRESIDENT, CLINICALDIAGNOSTICS | Diagnostics & Research | SALE | $202.30 | 3,000 | $606,899 | 147,882 | -2.0% |
| 2026-04-04 01:05 | 2026-04-01 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | SALE | $203.31 | 8,400 | $1,707,814 | 224,885 | -3.6% |
| 2026-04-02 11:17 | 2026-03-31 | BNR | Burning Rock Biotech Ltd | Han Yusheng | Director | Diagnostics & Research | BUY | $17.36 | 314,870 | $5,466,143 | 17,672,676 | +1.8% |
| 2026-03-30 22:29 | 2026-03-26 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | OPT+S | $25.55 | 4,172 | $106,599 | 3,058 | -57.7% |
| 2026-03-30 21:38 | 2026-03-26 | WGS | GeneDx Holdings Corp. | Feeley Kevin | Officer; CHIEF FINANCIAL OFFICER | Diagnostics & Research | OPT+S | $63.17 | 8,818 | $557,052 | 34,580 | -20.3% |
| 2026-03-30 21:30 | 2026-03-26 | WGS | GeneDx Holdings Corp. | Stueland Katherine | Director, Officer; CHIEF EXECUTIVE OFFICER | Diagnostics & Research | OPT+S | $63.17 | 46,933 | $2,964,842 | 91,514 | -33.9% |
| 2026-03-30 16:54 | 2026-03-27 | LH | LABCORP HOLDINGS INC. | Wilkinson Peter J | Officer; SVP, Chief Accounting Officer | Diagnostics & Research | SALE | $267.05 | 1,633 | $436,093 | 1,852 | -46.9% |
| 2026-03-30 16:44 | 2026-03-27 | LH | LABCORP HOLDINGS INC. | Meltzer Jonathan C | Officer; EVP, Operations | Diagnostics & Research | SALE | $267.05 | 839 | $224,055 | 3,620 | -18.8% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Diagnostics & Research | SALE | $43.79 | 354 | $15,500 | 137,903 | -0.3% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Green Paula | Officer; SVP of Human Resources | Diagnostics & Research | SALE | $43.79 | 297 | $13,005 | 124,104 | -0.2% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Diagnostics & Research | SALE | $43.79 | 1,742 | $76,276 | 858,887 | -0.2% |
| 2026-03-23 20:15 | 2026-03-19 | RDNT | RadNet, Inc. | Sorensen Alma Gregory | Director, Officer; Chief Strategy Officer | Diagnostics & Research | SALE | $62.20 | 15,000 | $933,014 | 1,208,923 | -1.2% |
| 2026-03-20 20:25 | 2026-03-20 | OPK | OPKO HEALTH, INC. | PAGANELLI JOHN A | Director | Diagnostics & Research | BUY | $1.14 | 10,000 | $11,350 | 394,340 | +2.6% |
| 2026-03-21 01:05 | 2026-03-18 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $198.75 | 4,570 | $908,301 | 21,032 | -17.9% |
| 2026-03-19 20:05 | 2026-03-17 | TWST | Twist Bioscience Corp | CHESS ROBERT | Director | Diagnostics & Research | OPT+S | $47.00 | 10,000 | $470,000 | 21,084 | -32.2% |
| 2026-03-19 21:16 | 2026-03-18 | GH | Guardant Health, Inc. | Tariq Musa | Director | Diagnostics & Research | SALE | $88.09 | 348 | $30,655 | 8,394 | -4.0% |
| 2026-03-19 20:45 | 2026-03-17 | MEDP | Medpace Holdings, Inc. | GEIGER JESSE J | Officer; President | Diagnostics & Research | OPT+S | $455.30 | 31,707 | $14,436,197 | 15,000 | -67.9% |
| 2026-03-19 20:21 | 2026-03-17 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | SALE | $25.91 | 19,300 | $500,098 | 21,479 | -47.3% |
| 2026-03-18 20:37 | 2026-03-16 | WAT | WATERS CORP /DE/ | Jiang Wei | Director | Diagnostics & Research | BUY | $289.46 | 500 | $144,730 | 3,441 | +17.0% |
| 2026-03-18 23:38 | 2026-03-18 | RDNT | RadNet, Inc. | Sorensen Alma Gregory | Director, Officer; Chief Strategy Officer | Diagnostics & Research | SALE | $62.15 | 15,000 | $932,280 | 1,223,923 | -1.2% |
| 2026-03-18 01:05 | 2026-03-13 | NTRA | Natera, Inc. | Chapman Rowan E | Director | Diagnostics & Research | SALE | $191.38 | 122 | $23,348 | 5,752 | -2.1% |
| 2026-03-17 22:46 | 2026-03-16 | GH | Guardant Health, Inc. | Bell Michael Brian | Officer; Chief Financial Officer | Diagnostics & Research | OPT+S | $87.04 | 3,000 | $261,111 | 43,601 | -6.4% |
| 2026-03-17 22:39 | 2026-03-16 | WGS | GeneDx Holdings Corp. | Feeley Kevin | Officer; CHIEF FINANCIAL OFFICER | Diagnostics & Research | OPT+S | $76.80 | 5,706 | $438,203 | 27,148 | -17.4% |
| 2026-03-17 22:40 | 2026-03-16 | WGS | GeneDx Holdings Corp. | Stueland Katherine | Director, Officer; CHIEF EXECUTIVE OFFICER | Diagnostics & Research | OPT+S | $76.80 | 17,179 | $1,319,291 | 58,447 | -22.7% |
| 2026-03-17 20:36 | 2026-03-13 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | SALE | $25.75 | 30,779 | $792,408 | 40,779 | -43.0% |
| 2026-03-17 01:05 | 2026-03-12 | NTRA | Natera, Inc. | Rabinowitz Matthew | Director, Officer; EXECUTIVE CHAIRMAN | Diagnostics & Research | OPT+S | $191.42 | 200,000 | $38,283,380 | 2,310,772 | -8.0% |
| 2026-03-16 20:07 | 2026-03-12 | CSTL | CASTLE BIOSCIENCES INC | Juvenal Tobin W | Officer; Chief Commercial Officer | Diagnostics & Research | SALE | $25.24 | 20,863 | $526,582 | 86,825 | -19.4% |
| 2026-03-13 20:10 | 2026-03-11 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | OPT+S | $25.67 | 44,125 | $1,132,821 | 71,558 | -38.1% |
| 2026-03-12 20:23 | 2026-03-11 | TMO | THERMO FISHER SCIENTIFIC INC. | Shafer Michael D | Officer; Executive Vice President | Diagnostics & Research | SALE | $499.40 | 1,607 | $802,536 | 20,950 | -7.1% |
| 2026-03-11 20:28 | 2026-03-09 | WGS | GeneDx Holdings Corp. | Feeley Kevin | Officer; CHIEF FINANCIAL OFFICER | Diagnostics & Research | OPT+S | $86.75 | 1,280 | $111,045 | 21,842 | -5.5% |
| 2026-03-11 20:26 | 2026-03-09 | WGS | GeneDx Holdings Corp. | Stueland Katherine | Director, Officer; CHIEF EXECUTIVE OFFICER | Diagnostics & Research | OPT+S | $86.75 | 3,678 | $319,059 | 44,955 | -7.6% |
| 2026-03-12 01:35 | 2026-03-10 | NTRA | Natera, Inc. | Chapman Steven Leonard | Director, Officer; CEO AND PRESIDENT | Diagnostics & Research | SALE | $204.13 | 5,623 | $1,147,838 | 156,607 | -3.5% |
| 2026-03-12 01:35 | 2026-03-10 | NTRA | Natera, Inc. | Brophy Michael Burkes | Officer; CHIEF FINANCIAL OFFICER | Diagnostics & Research | SALE | $204.13 | 785 | $160,244 | 63,354 | -1.2% |
| 2026-03-12 01:05 | 2026-03-10 | NTRA | Natera, Inc. | Fesko John | Officer; PRESIDENT, CHIEF BUS. OFFICER | Diagnostics & Research | SALE | $204.13 | 707 | $144,322 | 189,199 | -0.4% |
| 2026-03-12 01:05 | 2026-03-10 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $204.13 | 127 | $25,925 | 262,325 | 0.0% |
| 2026-03-12 01:05 | 2026-03-10 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | SALE | $204.13 | 1,745 | $356,212 | 233,285 | -0.7% |
| 2026-03-11 22:05 | 2026-03-10 | NTRA | Natera, Inc. | Moshkevich Solomon | Officer; PRESIDENT, CLINICALDIAGNOSTICS | Diagnostics & Research | SALE | $204.13 | 915 | $186,781 | 150,882 | -0.6% |
| 2026-03-10 20:06 | 2026-03-06 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer; Chief Accounting Officer | Diagnostics & Research | SALE | $46.43 | 246 | $11,421 | 54,799 | -0.4% |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Diagnostics & Research | SALE | $46.43 | 425 | $19,731 | 138,257 | -0.3% |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Green Paula | Officer; SVP of Human Resources | Diagnostics & Research | SALE | $46.43 | 935 | $43,408 | 124,401 | -0.7% |
| 2026-03-10 20:05 | 2026-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Diagnostics & Research | SALE | $46.43 | 2,423 | $112,490 | 860,629 | -0.3% |
| 2026-03-11 01:05 | 2026-03-06 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | OPT+S | $196.08 | 8,398 | $1,646,696 | 233,285 | -3.5% |
| 2026-03-10 23:50 | 2026-03-06 | SHC | Sotera Health Co | WARBURG PINCUS & CO. | Director, 10% owner | Diagnostics & Research | SALE | $15.27 | 15,000,000 | $229,050,000 | 19,102,952 | -44.0% |
| 2026-03-10 20:21 | 2026-03-06 | WAT | WATERS CORP /DE/ | FEARON RICHARD H | Director | Diagnostics & Research | BUY | $306.34 | 1,000 | $306,340 | 3,302 | +43.4% |
| 2026-03-10 22:10 | 2026-03-06 | SHC | Sotera Health Co | GTCR INVESTMENT XI LLC | Director, 10% owner | Diagnostics & Research | SALE | $15.27 | 10,000,000 | $152,700,000 | 12,735,301 | -44.0% |
| 2026-03-09 20:12 | 2026-03-05 | CSTL | CASTLE BIOSCIENCES INC | Cole G Bradley | Director | Diagnostics & Research | OPT+S | $28.47 | 7,403 | $210,727 | 19,309 | -27.7% |
| 2026-03-09 20:39 | 2026-03-05 | TMO | THERMO FISHER SCIENTIFIC INC. | CASPER MARC N | Director, Officer; Chairman & CEO | Diagnostics & Research | OPT+S | $514.82 | 4,000 | $2,059,262 | 123,925 | -3.1% |
| 2026-03-10 01:35 | 2026-03-05 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Diagnostics & Research | SALE | $48.48 | 8,441 | $409,246 | 642,084 | -1.3% |
| 2026-03-10 01:36 | 2026-03-05 | GRAL | GRAIL, Inc. | Ofman Joshua J. | Officer; President | Diagnostics & Research | SALE | $48.86 | 3,627 | $177,227 | 432,881 | -0.8% |
Strategic Analysis
Analyzing insider transactions within the Diagnostics & Research sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.